Spotlight On... Novartis faces whistleblower claims of bribery in Turkey; Acadia's Nuplazid wins FDA panel backing; Florida nurse practitioners on verge of winning script powers; and more...

Novartis ($NVS) faces bribery allegations in yet another country. A whistleblower has accused the Swiss drugmaker of paying bribes in Turkey to increase prescriptions of its drugs, Reuters reports. More

> An FDA advisory panel backed Acadia Pharmaceuticals' new Parkinson's disease drug Nuplazid for approval in a 12-2 vote. Report

> The time the FDA takes to review new drug applications is steadily decreasing, to an average of about 10 months in 2014, with the biggest gains in oncology. Report

> Lawmakers in Florida, the only remaining state that prohibits nurse practitioners from prescribing meds, passed a bill to grant them that power. Report

> Opko Health got a rejection letter from the FDA on its application for approval of its thyroid drug Rayaldee. Release

And Finally... Genetic testing to choose drug therapies helps treatment work better, but has to be repeated with relapses to keep benefits coming. Report

Suggested Articles

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.

The FDA approved GlaxoSmithKline's Nucala to treat hypereosinophilic syndrome, making it the first biologic approved for that disease.

There’s an emerging trend within the SMA community to pair treatments up in the hope that they may provide even better outcomes, one analyst notes.